Biomedical Research Education & Training
Faculty Member

Roden, Dan M., M.D.
Assistant Vice Chancellor for Personalized Medicine
Professor of Medicine
William Stokes Chair in Experimental Therapeutics
Professor of Pharmacology

Lab Url: http://oates.mc.vanderbilt.edu/rodenlab/index.php

Phone Number: 615-322-0067

Email Address: dan.roden@vanderbilt.edu

Roden, Dan's picture
Academic history
M.DC.M., McGill University, Montreal, Canada
Intern/Resident, Royal Victoria Hospital, Montreal, Canada
Fellowship, Vanderbilt University, Nashville, TN
Fellowship, Vanderbilt University, Nashville, TN
B.S, McGill University, Montreal, Canada

Office Address   Mailing Address

1285 Medical Research Building IV

1285-B MRB4 37232-0575


Research Keywords
Drug metabolism, Genetics, Heart, Ion transport, Knockout, Mouse, Pharmacokinetics, Pharmacology, Polymorphism

Patient Care Specialty
cardiac electophysiology

Research Specialty
Mechanisms and treatment of cardiac arrhythmias

Research Description
Abnormalities of cardiac rhythm are a common and serious public health problem. However, the therapies used to treat arrhythmias are often ineffective, and can sometimes even exacerbate arrhythmias. Research in this laboratory is directed at elucidating mechanisms underlying abnormalities of cardiac rhythm and mechanisms underlying variable responses to antiarrhythmic drug treatments. Since antiarrhythmic drugs affect the function of cardiac ion channels, it is one working hypothesis in the laboratory that variable responses to drug therapy may reflect variable function or expression of genes encoding ion channels or proteins involved in drug disposition. Thus, a major focus of work in the laboratory is elucidation of factor(s) that determine ion channel gene expression in cardiac tissue. Approaches include identification of new genes, identification of DNA polymorphisms and characterization of their functional effects on disease and drug responses, and modulation of expression in cultured heart cells (e.g. by antisense) and gene knockout in mice.

Clinical Interests
We are interested in variability in arrhythmia presentations and their response to therapies, particularly as a function of genetic background.

Publications
Delaney, JT, Jeff, JM, Brown, NJ, Pretorius, M, Okafor, HE, Darbar, D, Roden, DM, Crawford, DC. Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One, 7(2), e32338, 2012 PMCID:3285683

Delaney, JT, Muhammad, R, Blair, MA, Kor, K, Fish, FA, Roden, DM, Darbar, D. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace, 2012

Delaney, JT, Ramirez, AH, Bowton, E, Pulley, JM, Basford, MA, Schildcrout, JS, Shi, Y, Zink, R, Oetjens, M, Xu, H, Cleator, JH, Jahangir, E, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther, 91(2), 257-63, 2012 PMCID:3243123

Lowe, JS, Stroud, DM, Yang, T, Hall, L, Atack, TC, Roden, DM. Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res, 2012

Monahan, K, Brewster, J, Wang, L, Parvez, B, Goyal, S, Roden, DM, Darbar, D. Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. Am J Cardiol, 2012

Parvez, B, Chopra, N, Rowan, S, Vaglio, JC, Muhammad, R, Roden, DM, Darbar, D. A common I?1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol, 59(1), 49-56, 2012 PMCID:3243123

Pulley, JM, Denny, JC, Peterson, JF, Bernard, GR, Vnencak-Jones, CL, Ramirez, AH, Delaney, JT, Bowton, E, Brothers, K, Johnson, K, Crawford, DC, Schildcrout, J, Masys, DR, Dilks, HH, Wilke, RA, Clayton, EW, Shultz, E, Laposata, M, McPherson, J, Jirjis, JN, Roden, DM. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther, 92(1), 87-95, 2012 PMCID:3384438

Ramirez, AH, Shaffer, CM, Delaney, JT, Sexton, DP, Levy, SE, Rieder, MJ, Nickerson, DA, George, AL, Roden, DM. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J, 2012 PMCID:3384438

Ramirez, AH, Shi, Y, Schildcrout, JS, Delaney, JT, Xu, H, Oetjens, MT, Zuvich, RL, Basford, MA, Bowton, E, Jiang, M, Speltz, P, Zink, R, Cowan, J, Pulley, JM, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics, 13(4), 407-18, 2012 PMCID:3285683

Ritchie, MD, Rowan, S, Kucera, G, Stubblefield, T, Blair, M, Carter, S, Roden, DM, Darbar, D. Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. J Am Coll Cardiol, 2012

Roden, DM, Xu, H, Denny, JC, Wilke, RA. Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges. Clin Pharmacol Ther, 2012

Schildcrout, JS, Denny, JC, Bowton, E, Gregg, W, Pulley, JM, Basford, MA, Cowan, JD, Xu, H, Ramirez, AH, Crawford, DC, Ritchie, MD, Peterson, JF, Masys, DR, Wilke, RA, Roden, DM. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther, 92(2), 235-42, 2012

Wells, QS, Delaney, JT, Roden, DM. Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol, 27(3), 253-61, 2012 PMCID:3285683

Wilke, RA, Ramsey, LB, Johnson, SG, Maxwell, WD, McLeod, HL, Voora, D, Krauss, RM, Roden, DM, Feng, Q, Cooper-Dehoff, RM, Gong, L, Klein, TE, Wadelius, M, Niemi, M. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther, 92(1), 112-7, 2012 PMCID:3384438

Yang, T, Atack, TC, Stroud, DM, Zhang, W, Hall, L, Roden, DM. Blocking scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res, 111(3), 322-32, 2012

Atack, TC, Stroud, DM, Watanabe, H, Yang, T, Hall, L, Hipkens, SB, Lowe, JS, Leake, B, Magnuson, MA, Yang, P, Roden, DM. Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Circ Res, 109(1), 38-46, 2011 PMCID:3092760

Barrett, TW, Storrow, AB, Jenkins, CA, Harrell, FE, Miller, KF, Moser, KM, Russ, S, Roden, DM, Darbar, D. Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. J Cardiol, 58(2), 124-30, 2011 PMCID:3188836

Denny, JC, Crawford, DC, Ritchie, MD, Bielinski, SJ, Basford, MA, Bradford, Y, Chai, HS, Bastarache, L, Zuvich, R, Peissig, P, Carrell, D, Ramirez, AH, Pathak, J, Wilke, RA, Rasmussen, L, Wang, X, Pacheco, JA, Kho, AN, Hayes, MG, Weston, N, Matsumoto, M, Kopp, PA, Newton, KM, Jarvik, GP, Li, R, Manolio, TA, Kullo, IJ, Chute, CG, Chisholm, RL, Larson, EB, McCarty, CA, Masys, DR, Roden, DM, de Andrade, M. Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet, 89(4), 529-42, 2011 PMCID:3188836

Kannankeril, PJ, Norris, KJ, Carter, S, Roden, DM. Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm, 8(10), 1530-4, 2011 PMCID:3093198

Liu, M, Jiang, M, Kawai, VK, Stein, CM, Roden, DM, Denny, JC, Xu, H. Modeling drug exposure data in electronic medical records: an application to warfarin. AMIA Annu Symp Proc, 2011, 815-23, 2011 PMCID:3243123

Roden, DM. Personalized medicine and the genotype-phenotype dilemma. J Interv Card Electrophysiol, 31(1), 17-23, 2011 PMCID:3093198

Roden, DM, Johnson, JA, Kimmel, SE, Krauss, RM, Medina, MW, Shuldiner, A, Wilke, RA. Cardiovascular pharmacogenomics. Circ Res, 109(7), 807-20, 2011 PMCID:3188836

Roden, DM, Wilke, RA, Kroemer, HK, Stein, CM. Pharmacogenomics: the genetics of variable drug responses. Circulation, 123(15), 1661-70, 2011 PMCID:3093198

Turner, SD, Berg, RL, Linneman, JG, Peissig, PL, Crawford, DC, Denny, JC, Roden, DM, McCarty, CA, Ritchie, MD, Wilke, RA. Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS One, 6(5), e19586, 2011 PMCID:3092760

Watanabe, H, Yang, T, Stroud, DM, Lowe, JS, Harris, L, Atack, TC, Wang, DW, Hipkens, SB, Leake, B, Hall, L, Kupershmidt, S, Chopra, N, Magnuson, MA, Tanabe, N, Knollmann, BC, George, AL, Roden, DM. Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation, 124(9), 1001-11, 2011 PMCID:3188836

Xu, H, Jiang, M, Oetjens, M, Bowton, EA, Ramirez, AH, Jeff, JM, Basford, MA, Pulley, JM, Cowan, JD, Wang, X, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc, 18(4), 387-91, 2011 PMCID:3188836

Abraham, RL, Yang, T, Blair, M, Roden, DM, Darbar, D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol, 48(1), 181-90, 2010 PMCID:2740737

Chopra, SS, Stroud, DM, Watanabe, H, Bennett, JS, Burns, CG, Wells, KS, Yang, T, Zhong, TP, Roden, DM. Voltage-gated sodium channels are required for heart development in zebrafish. Circ Res, 106(8), 1342-50, 2010

Denny, JC, Ritchie, MD, Basford, MA, Pulley, JM, Bastarache, L, Brown-Gentry, K, Wang, D, Masys, DR, Roden, DM, Crawford, DC. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics, 26(9), 1205-10, 2010 PMCID:2859132

Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , . Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047-60, 2010 PMCID:2859132

Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , , , , , . Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol, 55(9), 934-47, 2010 PMCID:2859132

Ellinor, PT, Lunetta, KL, Glazer, NL, Pfeufer, A, Alonso, A, Chung, MK, Sinner, MF, de Bakker, PI, Mueller, M, Lubitz, SA, Fox, E, Darbar, D, Smith, NL, Smith, JD, Schnabel, RB, Soliman, EZ, Rice, KM, Van Wagoner, DR, Beckmann, BM, van Noord, C, Wang, K, Ehret, GB, Rotter, JI, Hazen, SL, Steinbeck, G, Smith, AV, Launer, LJ, Harris, TB, Makino, S, Nelis, M, Milan, DJ, Perz, S, Esko, T, K??ttgen, A, Moebus, S, Newton-Cheh, C, Li, M, M??hlenkamp, S, Wang, TJ, Kao, WH, Vasan, RS, N??then, MM, MacRae, CA, Stricker, BH, Hofman, A, Uitterlinden, AG, Levy, D, Boerwinkle, E, Metspalu, A, Topol, EJ, Chakravarti, A, Gudnason, V, Psaty, BM, Roden, DM, Meitinger, T, Wichmann, HE, Witteman, JC, Barnard, J, Arking, DE, Benjamin, EJ, Heckbert, SR, K????b, S. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet, 42(3), 240-4, 2010 PMCID:2859132

Limdi, NA, Wadelius, M, Cavallari, L, Eriksson, N, Crawford, DC, Lee, MT, Chen, CH, Motsinger-Reif, A, Sagreiya, H, Liu, N, Wu, AH, Gage, BF, Jorgensen, A, Pirmohamed, M, Shin, JG, Suarez-Kurtz, G, Kimmel, SE, Johnson, JA, Klein, TE, Wagner, MJ, , . Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 115(18), 3827-34, 2010 PMCID:2859132

Oshiro, C, Thorn, CF, Roden, DM, Klein, TE, Altman, RB. KCNH2 pharmacogenomics summary. Pharmacogenet Genomics, 2010 PMCID:2859132

Pulley, J, Clayton, E, Bernard, GR, Roden, DM, Masys, DR. Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci, 3(1), 42-8, 2010

Ritchie, MD, Denny, JC, Crawford, DC, Ramirez, AH, Weiner, JB, Pulley, JM, Basford, MA, Brown-Gentry, K, Balser, JR, Masys, DR, Haines, JL, Roden, DM. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet, 86(4), 560-72, 2010

Roden, DM. Brugada syndrome: lots of questions, some answers. Heart Rhythm, 7(1), 47-9, 2010 PMCID:2859132

Body, SC, Collard, CD, Shernan, SK, Fox, AA, Liu, KY, Ritchie, MD, Perry, TE, Muehlschlegel, JD, Aranki, S, Donahue, BS, Pretorius, M, Estrada, JC, Ellinor, PT, Newton-Cheh, C, Seidman, CE, Seidman, JG, Herman, DS, Lichtner, P, Meitinger, T, Pfeufer, A, K????b, S, Brown, NJ, Roden, DM, Darbar, D. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet, 2(5), 499-506, 2009 PMCID:2801871

Bush, WS, Crawford, DC, Alexander, C, George, AL, Roden, DM, Ritchie, MD. Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics, 10(6), 1043-53, 2009 PMCID:2746955

K????b, S, Darbar, D, van Noord, C, Dupuis, J, Pfeufer, A, Newton-Cheh, C, Schnabel, R, Makino, S, Sinner, MF, Kannankeril, PJ, Beckmann, BM, Choudry, S, Donahue, BS, Heeringa, J, Perz, S, Lunetta, KL, Larson, MG, Levy, D, MacRae, CA, Ruskin, JN, Wacker, A, Sch??mig, A, Wichmann, HE, Steinbeck, G, Meitinger, T, Uitterlinden, AG, Witteman, JC, Roden, DM, Benjamin, EJ, Ellinor, PT. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J, 30(7), 813-9, 2009 PMCID:2663727

Li, C, Schwarz, UI, Ritchie, MD, Roden, DM, Stein, CM, Kurnik, D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 113(17), 3925-30, 2009 PMCID:2673121

McBride, BF, Yang, T, Roden, DM. Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J, 9(3), 194-201, 2009 PMCID:2746955

Milan, DJ, Kim, AM, Winterfield, JR, Jones, IL, Pfeufer, A, Sanna, S, Arking, DE, Amsterdam, AH, Sabeh, KM, Mably, JD, Rosenbaum, DS, Peterson, RT, Chakravarti, A, K????b, S, Roden, DM, MacRae, CA. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation, 120(7), 553-9, 2009 PMCID:2727725

Postema, PG, Wolpert, C, Amin, AS, Probst, V, Borggrefe, M, Roden, DM, Priori, SG, Tan, HL, Hiraoka, M, Brugada, J, Wilde, AA. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 6(9), 1335-41, 2009 PMCID:2727725

Raj, SR, Stein, CM, Saavedra, PJ, Roden, DM. Cardiovascular effects of noncardiovascular drugs. Circulation, 120(12), 1123-32, 2009 PMCID:2727725

Roden, DM, Kannankeri, PJ, Darbar, D. Arrhythmia pharmacogenomics: methodological considerations. Curr Pharm Des, 15(32), 3734-41, 2009 PMCID:2788624

Watanabe, H, Chopra, N, Laver, D, Hwang, HS, Davies, SS, Roach, DE, Duff, HJ, Roden, DM, Wilde, AA, Knollmann, BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med, 15(4), 380-3, 2009 PMCID:2746955

Watanabe, H, Darbar, D, Kaiser, DW, Jiramongkolchai, K, Chopra, S, Donahue, BS, Kannankeril, PJ, Roden, DM. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol, 2(3), 268-75, 2009 PMCID:2727725

Watanabe, H, Kaiser, DW, Makino, S, MacRae, CA, Ellinor, PT, Wasserman, BS, Kannankeril, PJ, Donahue, BS, Roden, DM, Darbar, D. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm, 6(9), 1327-32, 2009 PMCID:2740737

Watanabe, H, Watanabe, T, Sasaki, S, Nagai, K, Roden, DM, Aizawa, Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J, 158(4), 629-36, 2009 PMCID:2727725

Yang, T, Chung, SK, Zhang, W, Mullins, JG, McCulley, CH, Crawford, J, MacCormick, J, Eddy, CA, Shelling, AN, French, JK, Yang, P, Skinner, JR, Roden, DM, Rees, MI. Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol, 2(4), 417-26, 2009 PMCID:2788624

Yang, T, Kanki, H, Zhang, W, Roden, DM. Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I(Ks) block by protein kinase A-mediated I(Ks) phosphorylation. Br J Pharmacol, 157(6), 952-61, 2009 PMCID:2746955

Darbar, D, Hardy, A, Haines, JL, Roden, DM. Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol, 51(11), 1083-9, 2008 PMCID:2279191

Darbar, D, Kannankeril, PJ, Donahue, BS, Kucera, G, Stubblefield, T, Haines, JL, George, AL, Roden, DM. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation, 117(15), 1927-35, 2008 PMCID:2365761

Darbar, D, Kimbrough, J, Jawaid, A, McCray, R, Ritchie, MD, Roden, DM. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol, 51(8), 836-42, 2008 PMCID:2271078

Kannankeril, PJ, Harris, PA, Norris, KJ, Warsy, I, Smith, PD, Roden, DM. Rate-Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise. J Cardiovasc Electrophysiol, 2008

Knollmann, BC, Roden, DM. A genetic framework for improving arrhythmia therapy. Nature, 451(7181), 929-36, 2008

Rhodes, TE, Abraham, RL, Welch, RC, Vanoye, CG, Crotti, L, Arnestad, M, Insolia, R, Pedrazzini, M, Ferrandi, C, Vege, A, Rognum, T, Roden, DM, Schwartz, PJ, George, AL. Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol, 44(3), 571-81, 2008 PMCID:2386856

Roden, D, Pulley, J, Basford, M, Bernard, G, Clayton, E, Balser, J, Masys, D. Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine. Clin Pharmacol Ther, 2008

Roden, DM. Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm, 5(8), 1213-5, 2008

Roden, DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol, 154(7), 1502-7, 2008 PMCID:2492095

Roden, DM. Clinical practice. Long-QT syndrome. N Engl J Med, 358(2), 169-76, 2008

Schwarz, UI, Ritchie, MD, Bradford, Y, Li, C, Dudek, SM, Frye-Anderson, A, Kim, RB, Roden, DM, Stein, CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 358(10), 999-1008, 2008

Watanabe, H, Koopmann, TT, Le Scouarnec, S, Yang, T, Ingram, CR, Schott, JJ, Demolombe, S, Probst, V, Anselme, F, Escande, D, Wiesfeld, AC, Pfeufer, A, K????b, S, Wichmann, HE, Hasdemir, C, Aizawa, Y, Wilde, AA, Roden, DM, Bezzina, CR. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest, 118(6), 2260-8, 2008 PMCID:2373423

Yang, P, Koopmann, TT, Pfeufer, A, Jalilzadeh, S, Schulze-Bahr, E, K????b, S, Wilde, AA, Roden, DM, Bezzina, CR. Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet, 16(3), 350-7, 2008

Chopra, SS, Watanabe, H, Zhong, TP, Roden, DM. Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates. BMC Evol Biol, 7, 113, 2007 PMCID:1971062

Darbar, D, Hardin, B, Harris, P, Roden, DM. A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol, 18(6), 636-41, 2007

Darbar, D, Motsinger, AA, Ritchie, MD, Gainer, JV, Roden, DM. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm, 4(6), 743-9, 2007 PMCID:1948880

Fitch, RW, Gregory, A, Darbar, D, Roden, DM. A shock in time. Clin J Sport Med, 17(6), 497-9, 2007

Kannankeril, PJ, Roden, DM. When should QT be measured? Summer solstice or Christmas Eve. Heart Rhythm, 4(3), 282-3, 2007

Kannankeril, PJ, Roden, DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol, 22(1), 39-43, 2007

Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Schott J-J, Norris K, Kim RB, Escande D, Roden DM:. Dysfunctional ankyrin-B variants with a spectrum of altered function are present in diverse human populations. . Circulation , 115, 432-441, 2007

Monahan, K, Clair, W, Roden, DM. A memorable experience. Europace, 2007

Pretorius, M, Donahue, BS, Yu, C, Greelish, JP, Roden, DM, Brown, NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation, 116(11 Suppl), I1-7, 2007

Roden, DM, Kannankeril, P, Darbar, D. On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace, 9 Suppl 4, iv1-3, 2007 PMCID:2599908

Smith, AH, Norris, KJ, Roden, DM, Kannankeril, PJ. Autonomic tone attenuates drug-induced QT prolongation. J Cardiovasc Electrophysiol, 18(9), 960-4, 2007

Bezzina CR, Shimizu W, Yang P, Koopmann T, Tanck MWT, Miyamoto Y, Kamakura S, Roden DM, Wilde AAM. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. . Circulation , 113, 338-344, 2006

Darbar, D, Roden, DM. Future of antiarrhythmic drugs. Curr Opin Cardiol, 21(4), 361-7, 2006

Darbar, D, Roden, DM. Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother, 7(12), 1583-90, 2006

Kannankeril, PJ, Bhuiyan, ZA, Darbar, D, Mannens, MM, Wilde, AA, Roden, DM. Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. Heart Rhythm, 3(8), 939-44, 2006

Kannankeril, PJ, Mitchell, BM, Goonasekera, SA, Chelu, MG, Zhang, W, Sood, S, Kearney, DL, Danila, CI, De Biasi, M, Wehrens, XH, Pautler, RG, Roden, DM, Taffet, GE, Dirksen, RT, Anderson, ME, Hamilton, SL. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A, 103(32), 12179-84, 2006 PMCID:1567715

Knollmann, BC, Chopra, N, Hlaing, T, Akin, B, Yang, T, Ettensohn, K, Knollmann, BE, Horton, KD, Weissman, NJ, Holinstat, I, Zhang, W, Roden, DM, Jones, LR, Franzini-Armstrong, C, Pfeifer, K. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest, 116(9), 2510-20, 2006 PMCID:1551934

Liu, K, Hipkens, S, Yang, T, Abraham, R, Zhang, W, Chopra, N, Knollmann, B, Magnuson, MA, Roden, DM. Recombinase-mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis, 44(11), 556-64, 2006

Motsinger, AA, Donahue, BS, Brown, NJ, Roden, DM, Ritchie, MD. Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pac Symp Biocomput, 584-95, 2006

Roden, DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med, 259(1), 59-69, 2006

Roden, DM, Altman, RB, Benowitz, NL, Flockhart, DA, Giacomini, KM, Johnson, JA, Krauss, RM, McLeod, HL, Ratain, MJ, Relling, MV, Ring, HZ, Shuldiner, AR, Weinshilboum, RM, Weiss, ST, , . Pharmacogenomics: challenges and opportunities. Ann Intern Med, 145(10), 749-57, 2006

Roden, DM, Anderson, ME. Proarrhythmia. Handb Exp Pharmacol(171), 73-97, 2006

Bezzina, CR, Wilde, AA, Roden, DM. The molecular genetics of arrhythmias. Cardiovasc Res, 67(3), 343-6, 2005

Crotti, L, Lundquist, AL, Insolia, R, Pedrazzini, M, Ferrandi, C, De Ferrari, GM, Vicentini, A, Yang, P, Roden, DM, George, AL, Schwartz, PJ. KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, 2005

Darbar, D, Roden, DM. Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm, 2(5), 544-9, 2005

Darbar, D, Roden, DM, Ali, MF, Yang, T, Wathen, MS. Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. Circulation, 111(11), e161, 2005

Darbar, D, Yang, T, Churchwell, K, Wilde, AA, Roden, DM. Unmasking of brugada syndrome by lithium. Circulation, 112(11), 1527-31, 2005 PMCID:1350464

Drolet, B, Simard, C, Mizoue, L, Roden, DM. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest, 115(8), 2209-13, 2005 PMCID:1174915

Kannankeril, PJ, Roden, DM, Norris, KJ, Whalen, SP, George, AL, Murray, KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm, 2(2), 134-40, 2005

Khoo, MS, Kannankeril, PJ, Li, J, Zhang, R, Kupershmidt, S, Zhang, W, Atkinson, JB, Colbran, RJ, Roden, DM, Anderson, ME. Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm, 2(6), 634-40, 2005

Liu, K, Yang, T, Viswanathan, PC, Roden, DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation, 112(21), 3239-46, 2005

Page RL, Roden DM. Drug therapy for atrial fibrillation. . Nature Drug Discovery, 4, 899-910, 2005

Roden DM. Principles of Clinical Pharmacology. . In Sixteenth Edition of Harrison?s Principles of Internal Medicine, 13-25, 2005

Roden DM and Temple R. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. . Circulation , 111, 1697-1702, 2005

Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. . J Clin Invest , 115, 2025-2032, 2005

Roden DM, Yang T. Editorial - Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. . Circulation , 112, 1376-1378, 2005

Roden DM:. An under-recognized challenge in evaluating post-marketing drug safety.. Circulation, 111, 246-8, 2005

Roden, DM. Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res, 67(3), 419-25, 2005

Roden, DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation, 111(3), 246-8, 2005

Roden, DM, Temple, R. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Circulation, 111(13), 1697-702, 2005

Roden, DM, Viswanathan, PC. Genetics of acquired long QT syndrome. J Clin Invest, 115(8), 2025-32, 2005 PMCID:1180553

Simard, C, Drolet, B, Yang, P, Kim, RB, Roden, DM. Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther, 77(3), 138-44, 2005

Temple, J, Frias, P, Rottman, J, Yang, T, Wu, Y, Verheijck, EE, Zhang, W, Siprachanh, C, Kanki, H, Atkinson, JB, King, P, Anderson, ME, Kupershmidt, S, Roden, DM. Atrial fibrillation in KCNE1-null mice. Circ Res, 97(1), 62-9, 2005

Todd, SJ, Campbell, MJ, Roden, DM, Kannankeril, PJ. Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm, 2(5), 540-3, 2005

Drolet, Benoit, Simard, Chantale, Roden, Dan M. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109(1), 26-9, 2004

Fenichel, RR, Malik, M, Antzelevitch, C, Sanguinetti, M, Roden, DM, Priori, SG, Ruskin, JN, Lipicky, RJ, Cantilena, LR, , . Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol, 15(4), 475-95, 2004 PMCID:1544371

Jay, PY, Harris, BS, Maguire, CT, Buerger, A, Wakimoto, H, Tanaka, M, Kupershmidt, S, Roden, DM, Schultheiss, TM, O'Brien, TX, Gourdie, RG, Berul, CI, Izumo, S. Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest, 113(8), 1130-7, 2004 PMCID:385399

Kanki, H, Kupershmidt, S, Yang, T, Wells, S, Roden, DM. A structural requirement for processing the cardiac K+ channel KCNQ1. J Biol Chem, 279(32), 33976-83, 2004

Kannankeril, PRINCE J., Roden, DAN M., Fish, FRANK A.. Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen''s Syndrome. J Cardiovasc Electrophysiol, 15(1), 119, 2004

Petersen, CI, McFarland, TR, Stepanovic, SZ, Yang, P, Reiner, DJ, Hayashi, K, George, AL, Roden, DM, Thomas, JH, Balser, JR. In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A, 101(32), 11773-8, 2004 PMCID:511051

Roden, DM. Human genomics and its impact on arrhythmias. Trends Cardiovasc Med, 14(3), 112-6, 2004

Roden, Dan M. Drug-induced prolongation of the QT interval. N Engl J Med, 350(10), 1013-22, 2004

Yang, Ping, Kupershmidt, Sabina, Roden, Dan M. Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc Res, 61(1), 56-65, 2004

Arad, Michael, Moskowitz, Ivan P, Patel, Vickas V, Ahmad, Ferhaan, Perez-Atayde, Antonio R, Sawyer, Douglas B, Walter, Mark, Li, Guo H, Burgon, Patrick G, Maguire, Colin T, Stapleton, David, Schmitt, Joachim P, Guo, X X, Pizard, Anne, Kupershmidt, Sabina, Roden, Dan M, Berul, Charles I, Seidman, Christine E, Seidman, J G. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation, 107(22), 2850-6, 2003

Drolet, Benoit, Yang, Tao, Daleau, Pascal, Roden, Dan M, Turgeon, Jacques. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol, 41(6), 934-7, 2003

Johnson, Walter H, Yang, Ping, Yang, Tao, Lau, Yung R, Mostella, Barbara A, Wolff, Daynna J, Roden, Dan M, Benson, D Woodrow. Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome. Pediatr Res, 53(5), 744-8, 2003

Kondo, Richard P, Anderson, Robert H, Kupershmidt, Sabina, Roden, Dan M, Evans, Sylvia M. Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol, 14(4), 383-91, 2003

Kupershmidt, Sabina, Yang, Iris C-H, Hayashi, Kenshi, Wei, Jian, Chanthaphaychith, Siprachanh, Petersen, Christina I, Johns, Daivid C, George, Alfred L, Roden, Dan M, Balser, Jeffrey R. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J, 17(15), 2263-5, 2003

Laohakunakorn, P, Benson, DW, Yang, P, Yang, T, Roden, DM, Kugler, JD. Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol, 92(8), 991-5, 2003

Roden, Dan M. Antiarrhythmic drugs: past, present and future. J Cardiovasc Electrophysiol, 14(12), 1389-96, 2003

Roden, Dan M. Cardiovascular pharmacogenomics. Circulation, 108(25), 3071-4, 2003

Roden, Dan M. A surprising new arrhythmia mechanism in heart failure. Circ Res, 93(7), 589-91, 2003

Roden, Dan M. Genetic polymorphisms, drugs, and proarrhythmia. J Interv Card Electrophysiol, 9(2), 131-5, 2003

Roden, Dan M. Antiarrhythmic drugs: past, present, and future. Pacing Clin Electrophysiol, 26(12), 2340-9, 2003

Yang, Tao, Kanki, Hideaki, Roden, Dan M. Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions. Circulation, 108(2), 132-4, 2003

Anderson, Mark E, Al-Khatib, Sana M, Roden, Dan M, Califf, Robert M, , . Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J, 144(5), 769-81, 2002

Gbadebo, T David, Trimble, Robert W, Khoo, Michelle S C, Temple, Joel, Roden, Dan M, Anderson, Mark E. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation, 105(6), 770-4, 2002

Kanki, Hideaki, Yang, Ping, Xie, Hong-Guang, Kim, Richard B, George, Alfred L, Roden, Dan M. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol, 13(3), 252-6, 2002

Kupershmidt, Sabina, Yang, Iris C-H, Sutherland, Margaret, Wells, K Sam, Yang, Tao, Yang, Ping, Balser, Jeffrey R, Roden, Dan M. Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous system. Cardiovasc Res, 56(1), 93-103, 2002

Kupershmidt, Sabina, Yang, Tao, Chanthaphaychith, Siprachanh, Wang, Zhiqing, Towbin, Jeffrey A, Roden, Dan M. Defective human Ether-? -go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem, 277(30), 27442-8, 2002

Roden, Dan M. The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol, 40(2), 357-9, 2002

Roden, Dan M, Balser, Jeffrey R, George, Alfred L, Anderson, Mark E. Cardiac ion channels. Annu Rev Physiol, 64, 431-75, 2002

Roden, Dan M, George, Alfred L. The genetic basis of variability in drug responses. Nat Rev Drug Discov, 1(1), 37-44, 2002

Tan, Hanno L, Kupershmidt, Sabina, Zhang, Rong, Stepanovic, Svetlana, Roden, Dan M, Wilde, Arthur A M, Anderson, Mark E, Balser, Jeffrey R. A calcium sensor in the sodium channel modulates cardiac excitability. Nature, 415(6870), 442-7, 2002

Wu, Yuejin, Temple, Joel, Zhang, Rong, Dzhura, Igor, Zhang, Wei, Trimble, Robert, Roden, Dan M, Passier, Robert, Olson, Eric N, Colbran, Roger J, Anderson, Mark E. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation, 106(10), 1288-93, 2002

Yang, Ping, Kanki, Hideaki, Drolet, Benoit, Yang, Tao, Wei, Jian, Viswanathan, Prakash C, Hohnloser, Stefan H, Shimizu, Wataru, Schwartz, Peter J, Stanton, Marshall, Murray, Katherine T, Norris, Kris, George, Alfred L, Roden, Dan M. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation, 105(16), 1943-8, 2002

Anderson, M E, Mazur, A, Yang, T, Roden, D M. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther, 296(3), 806-10, 2001

Darbar, D, Fromm, M F, Dellorto, S, Roden, D M. Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol, 12(1), 9-14, 2001

Mazur, A, Anderson, M E, Bonney, S, Roden, D M. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol, 37(4), 1100-5, 2001

Roden, D M. Defective ion channel function in the long QT syndrome: multiple unexpected mechanisms. J Mol Cell Cardiol, 33(2), 185-7, 2001

Roden, D M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res, 50(2), 224-31, 2001

Roden, D M. Principles in pharmacogenetics. Epilepsia, 42 Suppl 5, 44-8, 2001

Roden, D M, Brown, N J. Preprescription genotyping: not yet ready for prime time, but getting there. Circulation, 103(12), 1608-10, 2001

Roden, DM. QT bumps: unraveling the mechanisms. J Cardiovasc Electrophysiol, 12(12), 1379-80, 2001

Viswanathan, P C, Bezzina, C R, George, A L, Roden, D M, Wilde, A A, Balser, J R. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation, 104(10), 1200-5, 2001

Wu, J, Roden, D M, Wikswo, J P. Delayed activation and retrograde propagation in cardiac muscle: implication of virtual electrode effects. Ann Biomed Eng, 28(11), 1318-25, 2001

Yang, T, Snyders, D, Roden, D M. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol, 38(5), 737-44, 2001

Camm, A J, Janse, M J, Roden, D M, Rosen, M R, Cinca, J, Cobbe, S M. Congenital and acquired long QT syndrome. Eur Heart J, 21(15), 1232-7, 2000

Chiang, C E, Roden, D M. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol, 36(1), 1-12, 2000

Roden, D M. Impact of recent molecular studies on evaluation of ventricular arrhythmias. J Interv Card Electrophysiol, 4 Suppl 1, 7-16, 2000

Roden, D M. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol, 11(8), 938-40, 2000

Roden, D M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart, 84(3), 339-46, 2000 PMCID:1760959

Roden, D M, Anderson, M E. The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart, 84(3), 235-7, 2000 PMCID:1760962

Sesti, F, Abbott, G W, Wei, J, Murray, K T, Saksena, S, Schwartz, P J, Priori, S G, Roden, D M, George, A L, Goldstein, S A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A, 97(19), 10613-8, 2000 PMCID:27073

Tan HL, Kupershmidt S, Zhang R, Stepanovic S, Roden DM, Wilde AAM, Anderson ME, Balser JR. A Calcium Sensor in the Sodium Channel Modulates Cardiac Excitability. Nature, 415, 442-447, 2000

Wei, J, Fish, F A, Myerburg, R J, Roden, D M, George, A L. Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat, 15(4), 387-8, 2000

Wilde, A A, Roden, D M. Predicting the long-QT genotype from clinical data: from sense to science. Circulation, 102(23), 2796-8, 2000

Choy, A M, Darbar, D, Dell''Orto, S, Roden, D M. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol, 34(2), 396-401, 1999

Fromm, M F, Darbar, D, Dell''Orto, S, Roden, D M. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther, 290(1), 253-8, 1999

Fromm, M F, Kim, R B, Stein, C M, Wilkinson, G R, Roden, D M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments. Circulation, 99(4), 552-7, 1999

Fromm, M F, Leake, B, Roden, D M, Wilkinson, G R, Kim, R B. Human MRP3 transporter: identification of the 5''-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta, 1415(2), 369-74, 1999

Kim, R B, Wandel, C, Leake, B, Cvetkovic, M, Fromm, M F, Dempsey, P J, Roden, M M, Belas, F, Chaudhary, A K, Roden, D M, Wood, A J, Wilkinson, G R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res, 16(3), 408-14, 1999

Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA, Roden DM. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circulation Research, 84, 146-152, 1999

Kupershmidt, S, Yang, T, Anderson, M E, Wessels, A, Niswender, K D, Magnuson, M A, Roden, D M. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circ Res, 84(2), 146-52, 1999

Mazur, A, Roden, D M, Anderson, M E. Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation, 100(24), 2437-42, 1999

Nattel, S, Roden, D M, Escande, D. A spotlight on electrophysiological remodeling and the molecular biology of ion channels. Cardiovasc Res, 42(2), 267-9, 1999

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J, 20(3), 174-95, 1999

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation, 99(4), 518-28, 1999

Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation, 99(5), 674-81, 1999

Roden, D M. Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. Am J Cardiol, 84(9A), 29R-36R, 1999

Roden, D M. An overview of contemporary approaches to antiarrhythmic therapy. Jpn Circ J, 63(9), 655-8, 1999

Roden, D M, Balser, J R. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc Res, 44(2), 242-6, 1999

Roden, D M, Kupershmidt, S. From genes to channels: normal mechanisms. Cardiovasc Res, 42(2), 318-26, 1999

Roden, D M, Spooner, P M. Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol, 10(12), 1664-83, 1999

Roden, D M, Wilde, A A. Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity. J Cardiovasc Electrophysiol, 10(2), 219-23, 1999

Wei, J, Wang, D W, Alings, M, Fish, F, Wathen, M, Roden, D M, George, A L. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation, 99(24), 3165-71, 1999

Wu, Y, Roden, D M, Anderson, M E. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res, 84(8), 906-12, 1999

Choy, A M, Lang, C C, Roden, D M, Robertson, D, Wood, A J, Robertson, R M, Biaggioni, I. Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J, 136(4 Pt 1), 664-71, 1998

Darbar, D, Fromm, M F, Dell''Orto, S, Kim, R B, Kroemer, H K, Eichelbaum, M, Roden, D M. Modulation by dietary salt of verapamil disposition in humans. Circulation, 98(24), 2702-8, 1998

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 101, 289-294, 1998

Kim, R B, Fromm, M F, Wandel, C, Leake, B, Wood, A J, Roden, D M, Wilkinson, G R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 101(2), 289-94, 1998 PMCID:508566

Kupershmidt S, Snyders DJ, Raes A, Roden DM. A K+ channel splice variant common in human heart lacks a C- terminal domain required for expression of rapidly-activating delayed rectifier current. J. Biol. Chem., 273, 27231-27235, 1998

Kupershmidt S, Yang T, Roden DM. Modulation of cardiac sodium current phenotype by beta1-subunit expression. Circ , 83, 441-447, 1998

Kupershmidt, S, Snyders, D J, Raes, A, Roden, D M. A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem, 273(42), 27231-5, 1998

Kupershmidt, S, Yang, T, Roden, D M. Modulation of cardiac Na+ current phenotype by beta1-subunit expression. Circ Res, 83(4), 441-7, 1998

Roden, D M. Cardiovascular and Renal Advisory Panel of the FDA. Circulation, 97(12), 1107, 1998

Roden, D M. Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol, 21(5), 1029-34, 1998

Roden, D M. Mechanisms and management of proarrhythmia. Am J Cardiol, 82(4A), 49I-57I, 1998

Thadani, U, Roden, D M. FDA Panel report: January 1998. Circulation, 97(23), 2295-6, 1998

Vitola, J, Vukanovic, J, Roden, D M. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol, 9(10), 1109-13, 1998

Choy, A M, Lang, C C, Chomsky, D M, Rayos, G H, Wilson, J R, Roden, D M. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 96(7), 2149-54, 1997

Darbar, D, Dell''Orto, S, M??rike, K, Wilkinson, G R, Roden, D M. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther, 61(3), 292-300, 1997

Kupershmidt ,S., Sutherland, M., King, D., Magnuson,M.A., Roden, D.M. Replacement by homologous recombination of the minK gene with lacZ reveals cell-specific minK expression. Biophys. J, 72, A226, 1997

Roden, D M. A practical approach to torsade de pointes. Clin Cardiol, 20(3), 285-90, 1997

Roden, D M, George, A L. Structure and function of cardiac sodium and potassium channels. Am J Physiol, 273(2 Pt 2), H511-25, 1997

Yang, T, Snyders, D J, Roden, D M. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res, 80(6), 782-9, 1997

Yang, T, Snyders, D J, Roden, D M. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther, 280(3), 1170-5, 1997

Yang, T., Snyders, D.J., Roden, D.M. Rapid inactivation determines the rectification and [K+]o-dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ. Res., 80, 782-789, 1997

Yang, T., Snyders, D.J., Roden, D.M. Inhibition of cardiac potassium currents by the vesnarinone analog OPC- 18790: Comparison with quinidine and dofetilide. J. Phannacol.Exp. Ther., 280, 1170-1175, 1997

Choy, A.M.J., Darbar, D., Dell'Orto, S., Roden, D.M. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. Circulation, 94, 1202, 1996

Darbar, D, Dell''Orto, S, Wilkinson, G R, Roden, D M. Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Am J Health Syst Pharm, 53(6), 655-8, 1996

Darbar, D, Smith, M, M??rike, K, Roden, D M. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Am J Cardiol, 77(15), 1351-5, 1996

Darbar, D., Smith, M., M?rike, K., Roden, D.M. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pre-treatment with propranolol and diltiazem. Am. J. Cardiol, 77, 1351-1355, 1996

Fritz, JD, Robertson, D. Gene targeting approaches to the autonomic nervous system. J Auton Nerv Syst, 61(1), 1-5, 1996

Kennedy, C J, Roden, D M, McAllister, I L. Suprachoroidal effusion following argon laser trabeculoplasty. Aust N Z J Ophthalmol, 24(3), 279-82, 1996

Roden, D M. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol, 78(4A), 12-6, 1996

Roden, D M. Is there a need for new antiarrhythmic drugs. Arch Mal Coeur Vaiss, 89 Spec No 1, 13-8, 1996

Roden, D M. Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. Circulation, 94(7), 1499-502, 1996

Roden, D M, George, A L. The cardiac ion channels: relevance to management of arrhythmias. Annu Rev Med, 47, 135-48, 1996

Roden, D M, Lazzara, R, Rosen, M, Schwartz, P J, Towbin, J, Vincent, G M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation, 94(8), 1996-2012, 1996

Roden, D.M. Ibutilide and treatment of atrial arrhythmias (Editorial). Circulation, 94, 1499-1502, 1996

Roden, D.M., George, A.L. Jr. The cardiac ion channels: Relevance to management of arrhythmias. Annu. Rev. Med, 47, 135-148, 1996

Roden, D.M., Lazzara, R., Rosen, M.R., Schwartz, P.J., Vincent, G.M., for the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation, 94, 1996-2012, 1996

Rogers, RD, Bond, AH, Roden, DM. Structural Chemistry of Poly(ethylene glycol) Complexes of Lead(II) Nitrate and Lead(II) Bromide. Inorg Chem, 35(24), 6964-6973, 1996

Yang, T, Roden, D M. Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am J Physiol, 271(2 Pt 2), H541-7, 1996

Yang, T, Roden, D M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation, 93(3), 407-11, 1996

Yang, T., Roden, D.M. Extracellular potassium modulation of drug block of IKr: Implications for Torsades de Pointes and reverse use-dependence. Circulation, 93, 407-411, 1996

Yang, T., Roden, D.M. Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am. J. Physiol, 271, H541-H547, 1996

Echt, D S, Lee, J T, Murray, K T, Vorperian, V, Borganelli, S M, Crawford, D M, Friedrich, T, Roden, D M. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol, 6(9), 687-99, 1995

Echt, D.S., Lee, J.T., Murray, K.T., Vorperian, V., Borganelli, S.M., Crawford, D.M., Friedrich, T., Roden, D.M. A randomized, double-blind, placebo-controlled dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophys, 6, 687-699, 1995

Roden, D M, George, A L, Bennett, P B. Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol, 6(11), 1023-31, 1995

Roden, D.M. Antiarrhythmic drugs. The Pharmacological Basis of Therapeutics, 9th Edition, 839-874, 1995

Roden, D.M., George, A.L. Jr, Bennett, P.B. Recent advances in understanding the molecular mechanisms of the long QT syndrome. Invited review. J. Cardiovasc. Electrophysiol, 6, 1023-1031, 1995

Wei, J., Wathen, M., Murray, K., Daw, R., Roden, D., George, A.L. Jr. Absence of HERG and SCN5A mutations in acquired long QT syndrome. Circulation, 92, 1-275, 1995

Yang, T, Kupershmidt, S, Roden, D M. Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Circ Res, 77(6), 1246-53, 1995

Yang, T, Prakash, C, Roden, D M, Snyders, D J. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol, 115(2), 267-74, 1995 PMCID:1908306

Yang, T, Snyders, D J, Roden, D M. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation, 91(6), 1799-806, 1995

Yang, T., Kupershmidt, S., Roden, D.M. Anti-minK antisense decreases the amplitude of the rapidly-activating cardiac delayed rectifier K+ current. Circ. Res, 77, 1246-1253, 1995

Yang, T., Prakash, C., Roden, D.M., Snyders, D.J. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. J. Pharmacol, 15, 267-274, 1995

Yang, T., Snyders, D.J., Roden, D.M. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed rectifier K+ current (IKr) in AT- I cells: Concentration-, time-, voltage- and use-dependent effects. Circulation, 91, 1799-1806, 1995

Echt, D S, Gremillion, S T, Lee, J T, Roden, D M, Murray, K T, Borganelli, M, Crawford, D M, Stewart, J R, Hammon, J W. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol, 5(9), 752-60, 1994

M??rike, K E, Roden, D M. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther, 55(1), 28-34, 1994

Roden, D M. Mirror, mirror on the wall ... stereochemistry in therapeutics. Circulation, 89(5), 2451-3, 1994

Roden, D M. Risks and benefits of antiarrhythmic therapy. N Engl J Med, 331(12), 785-91, 1994

Roden, D M, Levy, F E. Oncocytoma of the parotid gland presenting with nerve paralysis. Otolaryngol Head Neck Surg, 110(6), 587-90, 1994

Roden, D.M. Risks and benefits of antiarrhythmic therapy. Invited review. N. Engl. J. Med., , 331, 785-791, 1994

Roden, D.M. Mirror, mirror on the wall: Stereochemistry in therapeutics (Editorial). Circulation, 89, 2451-2453, 1994

Roden, D.M., Murray, K.T. Pharmacokinetics, phannacodynamics and pharmacogenetics. Zipes, D.P., Jalife, J. (eds): Cardiac Electrophysiology: From Cell to Bedside, 2nd edition, W.B. Saunders, 1287-1296, 1994

Roden, D.M., Tamkun, M.M. Toward a molecular view of cardiac arrhythmogenesis. Trends Cardiovasc. Med. , 4, 278-285, 1994

Turgeon, J, Daleau, P, Bennett, P B, Wiggins, S S, Selby, L, Roden, D M. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res, 75(5), 879-86, 1994

Turgeon, J., Daleau, P., Bennett, P.B., Wiggins, S.S., Selby, L., Roden, D.M. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ. Res, 75, 879-886, 1994

Vorperian, V R, Wisialowski, T A, Deegan, R, Roden, D M. Effect of hypercapnic acidemia on anisotropic propagation in the canine ventricle. Circulation, 90(1), 456-61, 1994

Yang, T, Wathen, M S, Felipe, A, Tamkun, M M, Snyders, D J, Roden, D M. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res, 75(5), 870-8, 1994

Yang, T., Wathen, M.S., Felipe, A., Tamkun, M.M., Snyders, D.J., Roden, D.M. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ. Res, 75, 870-878, 1994

Davies, R F, Siddoway, L A, Shaw, L, Barbey, J T, Roden, D M, Woosley, R L. Immediate- versus controlled-release disopyramide: importance of saturable binding. Clin Pharmacol Ther, 54(1), 16-22, 1993

Roden, D M. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J, 14 Suppl H, 56-61, 1993

Roden, D M. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol, 72(16), 45F-50F, 1993

Roden, D M. Torsade de pointes. Clin Cardiol, 16(9), 683-6, 1993

Roden, D M. Current status of class III antiarrhythmic drug therapy. Am J Cardiol, 72(6), 44B-49B, 1993

Roden, D M. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol, 72(4), 51A-55A, 1993

Roden, D M, Pomerantz, R A. Penetrating injuries to the neck: a safe, selective approach to management. Am Surg, 59(11), 750-3, 1993

Birgersdotter, U M, Wong, W, Turgeon, J, Roden, D M. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol, 33(3), 275-80, 1992 PMCID:1381275

Greene, H L, Roden, D M, Katz, R J, Woosley, R L, Salerno, D M, Henthorn, R W. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol, 19(5), 894-8, 1992

Turgeon, J, Wisialowski, T A, Wong, W, Altemeier, W A, Wikswo, J P, Roden, D M. Suppression of longitudinal versus transverse conduction by sodium channel block. Effects of sodium bolus. Circulation, 85(6), 2221-6, 1992

Wong, W, Pavlou, H N, Birgersdotter, U M, Hilleman, D E, Mohiuddin, S M, Roden, D M. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol, 69(3), 206-12, 1992

Balser, J R, Bennett, P B, Hondeghem, L M, Roden, D M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res, 69(2), 519-29, 1991

Balser, J R, Roden, D M, Bennett, P B. Single inward rectifier potassium channels in guinea pig ventricular myocytes. Effects of quinidine. Biophys J, 59(1), 150-61, 1991 PMCID:1281127

Balser, J.R., Bennett, P.B., Hondeghem, L.M., Roden, D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone. Circ. Res., 69, 519-529, 1991

Pavlou, H N, Funck-Brentano, C, Lineberry, M D, Woosley, R L, Roden, D M. Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. Clin Pharmacol Ther, 49(3), 314-21, 1991

Tamkun, M M, Knoth, K M, Walbridge, J A, Kroemer, H, Roden, D M, Glover, D M. Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J, 5(3), 331-7, 1991

Turgeon, J, Evans, W E, Relling, M V, Wilkinson, G R, Roden, D M. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol, 32(3), 283-8, 1991 PMCID:1368519

Turgeon, J, Funck-Brentano, C, Gray, H T, Pavlou, H N, Prakash, C, Blair, I A, Roden, D M. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther, 49(5), 488-96, 1991

Ware, D L, Lee, J T, Murray, K T, Hanyok, J J, Roden, D M, Echt, D S. Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study. Pacing Clin Electrophysiol, 14(9), 1343-50, 1991

Wikswo, J P, Wisialowski, T A, Altemeier, W A, Balser, J R, Kopelman, H A, Roden, D M. Virtual cathode effects during stimulation of cardiac muscle. Two-dimensional in vivo experiments. Circ Res, 68(2), 513-30, 1991

Balser, J R, Bennett, P B, Roden, D M. Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier. J Gen Physiol, 96(4), 835-63, 1990 PMCID:2229010

Balser, J R, Roden, D M, Bennett, P B. Global parameter optimization for cardiac potassium channel gating models. Biophys J, 57(3), 433-44, 1990 PMCID:1280738

Balser, J.R., Bennett, P.B., Roden, D.M. Time-dependent outward current in guinea pig myocytes: Gating kinetics of the delayed rectifier. J. Gen. Physiol, 96, 835-863, 1990

Campbell, R M, Woosley, R L, Iansmith, D H, Roden, D M. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. Pacing Clin Electrophysiol, 13(1), 30-6, 1990

Fish, F A, Prakash, C, Roden, D M. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation, 82(4), 1362-9, 1990

Funck-Brentano, C, Kroemer, H K, Lee, J T, Roden, D M. Propafenone. N Engl J Med, 322(8), 518-25, 1990

Funck-Brentano, C, Silberstein, D J, Roden, D M, Wood, A J, Woosley, R L. A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. Br J Clin Pharmacol, 30(2), 195-202, 1990 PMCID:1368218

Lee, J T, Kroemer, H K, Silberstein, D J, Funck-Brentano, C, Lineberry, M D, Wood, A J, Roden, D M, Woosley, R L. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med, 322(25), 1764-8, 1990

Murray, K T, Reilly, C, Koshakji, R P, Roden, D M, Lineberry, M D, Wood, A J, Siddoway, L A, Barbey, J T, Woosley, R L. Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest, 85(3), 836-42, 1990 PMCID:296501

Turgeon, J, Kroemer, H K, Prakash, C, Blair, I A, Roden, D M. Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci, 79(2), 91-5, 1990

Turgeon, J, Pavlou, H N, Wong, W, Funck-Brentano, C, Roden, D M. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther, 255(2), 642-9, 1990

Zhou, H H, Anthony, L B, Roden, D M, Wood, A J. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther, 47(6), 686-93, 1990

Bajaj, A K, Woosley, R L, Roden, D M. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation, 80(4), 994-1002, 1989

Davies, R F, Lineberry, M D, Funck-Brentano, C, Echt, D S, Lee, J T, Capuzzi, D M, Roden, D M, Woosley, R L. Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Clin Pharmacol Ther, 46(3), 324-34, 1989

Fish, F A, Roden, D M. A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs. Med Toxicol Adverse Drug Exp, 4(6), 400-11, 1989

Funck-Brentano, C, Kroemer, H K, Pavlou, H, Woosley, R L, Roden, D M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol, 27(4), 435-44, 1989 PMCID:1379722

Funck-Brentano, C, Light, R T, Lineberry, M D, Wright, G M, Roden, D M, Woosley, R L. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. J Cardiovasc Pharmacol, 14(3), 364-73, 1989

Funck-Brentano, C, Turgeon, J, Woosley, R L, Roden, D M. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther, 249(1), 134-42, 1989

Greene, H L, Richardson, D W, Barker, A H, Roden, D M, Capone, R J, Echt, D S, Friedman, L M, Gillespie, M J, Hallstrom, A P, Verter, J. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(1), 1-6, 1989

Greene, H L, Richardson, D W, Hallstrom, A P, McBride, R, Capone, R J, Barker, A H, Roden, D M, Echt, D S. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(7), 393-8, 1989

Kroemer, H K, Funck-Brentano, C, Silberstein, D J, Wood, A J, Eichelbaum, M, Woosley, R L, Roden, D M. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation, 79(5), 1068-76, 1989

Kroemer, H K, Turgeon, J, Parker, R A, Roden, D M. Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther, 46(5), 584-90, 1989

Murray, K T, Barbey, J T, Kopelman, H A, Siddoway, L A, Echt, D S, Woosley, R L, Roden, D M. Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clin Pharmacol Ther, 45(5), 553-61, 1989

Roden, D M. Magnesium treatment of ventricular arrhythmias. Am J Cardiol, 63(14), 43G-46G, 1989

Roden, D M, Lee, J T, Woosley, R L, Echt, D S. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Circulation, 80(5), 1247-58, 1989

The CAST Investigators. Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. 321, N. Eng. J. Med, 406-412, 1989

Turgeon, J, Funck-Brentano, C, Gray, H T, Roden, D M. Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. J Chromatogr, 490(1), 165-74, 1989

Turgeon, J, Roden, D M. Pharmacokinetic profile of encainide. Clin Pharmacol Ther, 45(6), 692-4, 1989

Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Circulation, 77(2), 380-91, 1988

Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M. Tocainide plus quinidine for treatment of ventricular arrhythmias. Am J Cardiol, 61(8), 570-3, 1988

Kopelman, H A, Woosley, R L, Lee, J T, Roden, D M, Echt, D S. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol, 61(13), 1006-11, 1988

Roden, D M. Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol, 62(12), 34H-38H, 1988

Roden, D M, Bennett, P B, Snyders, D J, Balser, J R, Hondeghem, L M. Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res, 62(5), 1055-8, 1988

Roden, D M, Nadeau, J H, Primm, R K. Electrophysiologic and hemodynamic effects of chronic oral therapy with the alpha 2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther, 43(6), 648-54, 1988

Roden, D M, Woosley, R L. Clinical pharmacokinetics of encainide. Clin Pharmacokinet, 14(3), 141-7, 1988

Thompson, K A, Iansmith, D H, Siddoway, L A, Woosley, R L, Roden, D M. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther, 244(3), 950-5, 1988

Thompson, K A, Murray, J J, Blair, I A, Woosley, R L, Roden, D M. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther, 43(6), 636-42, 1988

Wang, T, Siddoway, L A, Thompson, K A, Conard, G J, Bergstrand, R H, Kvam, D, Roden, D M, Woosley, R L. The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. Clin Pharmacol Ther, 43(5), 499-508, 1988

Woosley, R L, Wood, A J, Roden, D M. Drug therapy. Encainide. N Engl J Med, 318(17), 1107-15, 1988

Bajaj, A K, Kopelman, H A, Wikswo, J P, Cassidy, F, Woosley, R L, Roden, D M. Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. Circulation, 75(5), 1065-73, 1987

Roden, D M, Iansmith, D H. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med, 82(3A), 18-23, 1987

Roden, D M, Iansmith, D H, Woosley, R L. Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther, 243(3), 1218-24, 1987

Siddoway, L A, Barbey, J T, Roden, D M, Woosley, R L. Pharmacologic evaluation of standard and controlled-release disopyramide. Angiology, 38(2 Pt 2), 184-7, 1987

Siddoway, L A, Thompson, K A, McAllister, C B, Wang, T, Wilkinson, G R, Roden, D M, Woosley, R L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation, 75(4), 785-91, 1987

Thompson, K A, Blair, I A, Woosley, R L, Roden, D M. Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther, 241(1), 84-90, 1987

Woosley, R L, Roden, D M. Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol, 59(11), 19E-25E, 1987

Bergstrand, R H, Wang, T, Roden, D M, Avant, G R, Sutton, W W, Siddoway, L A, Wolfenden, H, Woosley, R L, Wilkinson, G R, Wood, A J. Encainide disposition in patients with chronic cirrhosis. Clin Pharmacol Ther, 40(2), 148-54, 1986

Bergstrand, R H, Wang, T, Roden, D M, Stone, W J, Wolfenden, H T, Woosley, R L, Wilkinson, G R, Wood, A J. Encainide disposition in patients with renal failure. Clin Pharmacol Ther, 40(1), 64-70, 1986

Duff, H J, Kolodgie, F D, Roden, D M, Woosley, R L. Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol, 8(4), 840-6, 1986

Hammon, J W, Echt, D S, Merrill, W H, Primm, K R, Woosley, R L, Smith, R F, Roden, D M, Bender, H W. Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. Ann Surg, 203(6), 679-84, 1986 PMCID:1251204

Kolodgie, F D, Dawson, A K, Roden, D M, Forman, M B, Virmani, R. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Am Heart J, 112(6), 1192-201, 1986

Roden, D M. Pharmacologic information required for design of programmed electrical stimulation protocols. Circulation, 73(2 Pt 2), II39-44, 1986

Roden, D M, Thompson, K A, Hoffman, B F, Woosley, R L. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol, 8(1 Suppl A), 73A-78A, 1986

Roden, D M, Wood, A J, Wilkinson, G R, Woosley, R L. Disposition kinetics of encainide and metabolites. Am J Cardiol, 58(5), 4C-9C, 1986

Roden, D M, Woosley, R L. Drug therapy. Tocainide. N Engl J Med, 315(1), 41-5, 1986

Roden, D M, Woosley, R L. Drug therapy. Flecainide. N Engl J Med, 315(1), 36-41, 1986

Roden, D M, Woosley, R L, Primm, R K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J, 111(6), 1088-93, 1986

Wang, T, Bergstrand, R H, Thompson, K A, Siddoway, L A, Duff, H J, Woosley, R L, Roden, D M. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol, 57(13), 1160-5, 1986

Woosley, R L, Echt, D S, Roden, D M. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol, 57(3), 25B-33B, 1986

Woosley, R L, Roden, D M, Dai, G H, Wang, T, Altenbern, D, Oates, J, Wilkinson, G R. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther, 39(3), 282-7, 1986

Duff, H J, Roden, D M, Carey, E L, Wang, T, Primm, R K, Woosley, R L. Spectrum of antiarrhythmic response to encainide. Am J Cardiol, 56(13), 887-91, 1985

Duff, H J, Roden, D M, Yacobi, A, Robertson, D, Wang, T, Maffucci, R J, Oates, J A, Woosley, R L. Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. Am J Cardiol, 55(4), 395-401, 1985

Roden, D M. Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents. Postgrad Med, 78(4), 28-37, 1985

Roden, D M. Tocainide and mexiletine. Orally effective lidocaine analogues. Arch Intern Med, 145(3), 417-8, 1985

Roden, D M, Hoffman, B F. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res, 56(6), 857-67, 1985

Roden, D M, Woosley, R L. QT prolongation and arrhythmia suppression. Am Heart J, 109(2), 411-5, 1985

Roden, D.M., Hoffman, B. Action potential prolongation and induction of abnormnal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length. Circ. Res, 56, 857-867, 1985

Siddoway, L A, Roden, D M, Woosley, R L. Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovasc Clin, 15(3), 199-248, 1985

Woosley, R L, Echt, D S, Roden, D M. Treatment of ventricular arrhythmias in the failing heart: pharmacologic and clinical considerations. Ration Drug Ther, 19(10), 1-7, 1985

Carey, E L, Duff, H J, Roden, D M, Primm, R K, Wilkinson, G R, Wang, T, Oates, J A, Woosley, R L. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest, 73(2), 539-47, 1984 PMCID:425046

Dawson, A K, Roden, D M, Duff, H J, Woosley, R L, Smith, R F. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol, 54(6), 654-8, 1984

Duff, H J, Oates, J A, Roden, D M, Woosley, R L. The antiarrhythmic activity of meobentine sulfate in man. J Cardiovasc Pharmacol, 6(4), 650-6, 1984

Duff, H J, Roden, D M, Marney, S, Colley, D G, Maffucci, R, Primm, R K, Oates, J A, Woosley, R L. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. Am Heart J, 107(3), 585-9, 1984

Riddell, J G, McAllister, C B, Wilkinson, G R, Wood, A J, Roden, D M. A new method for constant plasma drug concentrations: application to lidocaine. Ann Intern Med, 100(1), 25-8, 1984

Roden, D M, Dawson, A K, Duff, H J, Woosley, R L, Smith, R F. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. J Cardiovasc Pharmacol, 6(4), 588-95, 1984

Siddoway, L A, Roden, D M, Woosley, R L. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol, 54(9), 9D-12D, 1984

Wang, T, Roden, D M, Wolfenden, H T, Woosley, R L, Wood, A J, Wilkinson, G R. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther, 228(3), 605-11, 1984

Woosley, R L, Cerskus, I, Roden, D M. Antiarrhythmic therapy: clinical pharmacology update. J Clin Pharmacol, 24(7), 295-305, 1984

Woosley, R L, Siddoway, L A, Duff, H J, Roden, D M. Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol, 53(5), 59B-65B, 1984

Woosley, R L, Siddoway, L A, Thompson, K, Cerskus, I, Roden, D M. Potential applications of free drug level monitoring in cardiovascular therapy. Clin Pharmacokinet, 9 Suppl 1, 79-83, 1984

Duff, H J, Dawson, A K, Roden, D M, Oates, J A, Smith, R F, Woosley, R L. Electrophysiologic actions of O-demethyl encainide: an active metabolite. Circulation, 68(2), 385-91, 1983

Duff, H J, Roden, D M, Brorson, L, Wood, A J, Dawson, A K, Primm, R K, Oates, J A, Smith, R F, Woosley, R L. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol, 2(6), 1134-40, 1983

Roden, D M, Woosley, R L. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. Pharmacol Ther, 23(2), 179-91, 1983

Siddoway, L A, McAllister, C B, Wilkinson, G R, Roden, D M, Woosley, R L. Amiodarone dosing: a proposal based on its pharmacokinetics. Am Heart J, 106(4 Pt 2), 951-6, 1983

Woosley, R L, Roden, D M. Importance of metabolites in antiarrhythmic therapy. Am J Cardiol, 52(6), 3C-7C, 1983

Duff, H J, Roden, D M, Dawson, A K, Oates, J A, Smith, R F, Woosley, R L. Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. Am J Cardiol, 50(2), 305-12, 1982

Roden, D M, Duff, H J, Altenbern, D, Woosley, R L. Antiarrhythmic activity of the O-demethyl metabolite of encainide. J Pharmacol Exp Ther, 221(3), 552-7, 1982

Woosley, R L, Reele, S B, Roden, D M, Nies, A S, Oates, J A. Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. Clin Pharmacol Ther, 32(3), 313-21, 1982

Woosley, R L, Roden, D M, Duff, H J, Oates, J A. Selection of an antiarrhythmic drug for a sudden-death-prevention trial. Am Heart J, 103(4 Pt 2), 737-45, 1982

Duff, H J, Roden, D M, Maffucci, R J, Vesper, B S, Conard, G J, Higgins, S B, Oates, J A, Smith, R F, Woosley, R L. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol, 48(6), 1133-40, 1981

Roden, D M, Duff, H J, Primm, R K, Kronenberg, M W, Woosley, R L. Control of ventricular preexcitation and associated arrhythmias by encainide. Am Heart J, 102(4), 794-7, 1981

Roden, D M, Duff, H J, Reele, S B, Woosley, R L, Oates, J A, Smith, R F, Friesinger, G C. Recurrent ventricular tachycardia in the absence of overt heart disease: clinical characteristics and response to drug therapy. South Med J, 74(9), 1090-4, 1981

Roden, D M, Reele, S B, Higgins, S B, Mayol, R F, Gammans, R E, Oates, J A, Woosley, R L. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. N Engl J Med, 302(16), 877-82, 1980

Roden, D M, Reele, S B, Higgins, S B, Wilkinson, G R, Smith, R F, Oates, J A, Woosley, R L. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol, 46(3), 463-8, 1980

Roden, D M, Roden, D M, Reele, S B, Reele, S B, Higgins, S B, Higgins, S B, Carr, R K, Carr, R K, Smith, R F, Smith, R F, Oates, J A, Oates, J A, Woosley, R L, Woosley, R L. Tocainide therapy for refractory ventricular arrhythmias. Am Heart J, 100(1), 15-22, 1980


Postdoctoral Position Available
No

Postdoctoral Position Details
N/A

Updated Date
08/08/2012